Bicycle Therapeutics
The therapeutic modality draws on the scientific research of Professor Christian Heinis and Sir Greg Winter — winner of the 2018 Nobel Prize in Chemistry. Bicycles are a novel potential treatment for cancer and other diseases.
In oncology, the company’s proprietary cyclised molecule, the Bicycle®, is designed to deliver therapeutic agents into solid tumours with precision, and the firm is currently conducting clinical trials to test its compounds for clinical efficacy and safety before delivery of the technology to large patient populations with the aim of new medicines and better treatment outcomes.
In May 2024, Nasdaq-listed Bicycle raised $555m and extended its cash runway to 2027.
The company’s headquarters are in Cambridge, UK, with a biotech hub in Boston, US, where it trades on NASDAQ. Dr Kevin Lee is the CEO. In consecutive years (2022 and 2023), Bicycle Therapeutics won our Business of the Year and Quoted Company accolades.
